3rd ESTRO Forum 2015 1 SD -standard deviation 2 CR -complete response Conclusions: CT imaging allows detection of uterine perforation, as well as sub-serosal insertion of uterine tandem in CT-guided intracavitary HDR brachytherapy for cervix carcinoma. We report a relatively low incidence of these events, even without image guidance during applicators insertion.
the tandem and fixation mechanics, the needles were inserted more laterally to improve tumor coverage. Results: In MRI, the HR CTV maximum width was 4.1 cm, 3.5 cm right-sided and 0.6 cm left-sided from the tandem. HR CTV volume was 49 cm 3 . With the rotating ovoid technique, the position of needles at level of tumor maximum width was 0.5 cm shifted to right lateral side. And these resulted an improvement of D90 dose from 7.1 to 7.7 Gy and D98 dose from 5.8 to 6.3 Gy while decreasing doses to bladder and sigmoid. Conclusions: The novel technique of rotating ovoid-guided needles insertion was feasible and resulted improvement of dose coverage to tumor with remarkably laterally asymmetric geometry, and additionally diminish doses to surrounding normal organs.
EP-1599
Uterine perforation during three-dimensional image guided brachytherapy in cervical cancer ñ 3-year experience C. Ferreira 1 , A. Alzamora 1 , A. Pinho 2 , S. Pinto 2 , T. Viterbo 2 , A. Pereira 2 , L. Carvalho 1 , L. Salgado 1 1 Instituto Português de Oncologia do Porto, Radiotherapy, Porto, Portugal 2 Instituto Português de Oncologia do Porto, Medical Physics, Porto, Portugal Purpose/Objective: Cervical cancer is third most common female cancer and the fourth most common cause of cancer death. Combination of external beam radiation therapy (EBRT) with concomitant chemotherapy (CT) and brachytherapy (BT) is an essential treatment modality for this pathology. In intracavitary (IC) BT, an applicator is placed in uterine cavity and vaginal fornices. The accurate positioning of the IC applicator is of extreme importance for delivering the appropriate dose to the target volume, while keeping the surrounding tissues and organs with doses below their tolerance limits. Uterine perforation can lead to under dosage of the target volume and excessive dosage in the organs at risk, compromising local control of the disease and increasing the risk of acute and long-term complications. The aim of this work is to determine the incidence and characteristics of uterine perforation since the introduction of the 3D image-guided BT and its impact on the treatment of patients with cervical cancer. Materials and Methods: It was performed a retrospective analysis of clinical and radiological process of patients with cervical cancer treated with utero-vaginal image guided BT, between October/2011 and October/2104. Results: Between October/2011 and October/2014, 163 patients underwent utero-vaginal BT with curative intent, 314 applications were made. In all patients the treatment plan included EBRT (40 to 50 Gy) with concomitant CT. Uterine perforation occurred in 23 patients (14.1%) and in 27 applications (8.6%). The most common site of perforation was the uterine fundus, followed by the anterior and posterior wall. All patients were treated conservatively without complications. The treatment was feasible in 13 patients who had uterine perforation. In patients who suffered uterine perforation, the average diagnosis age was 55 years old (30 to 74 years old) and the average size of the cervix at diagnosis was 5 cm (3 to 7 cm). Six of these patients were submitted to previous cone biopsy and only 5 patients had retroflexed uterus.
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Conclusions: 3D image-guided BT allows accurate identification of uterine perforations, preventing potential acute and long term complications, while ensuring that the appropriated dose is delivered to the target volume.
EP-1600
Dosimetric study for cervical cancer brachytherapy comparing IGBT v.s. prescribing to Point A M. Zahra 1 , W. Keough 1 1 Western General Hospital Edinburgh Cancer Centre, Edinburgh Cancer Centre, Edinburgh, United Kingdom Purpose/Objective: Compare the dosimetry for plans generated by using the GEC -ESTRO guidelines with a traditional point A prescription in terms of tumourcoverage and dose to the OARs. Materials and Methods: The plans of 30 patients with cervical cancerwere reviewed, they all received EBRT to 45Gy in 25 fractions with concurrentcisplatin chemotherapy. They had 3 CT guided individualised fractions of HDR brachytherapyaiming for a d90 >80Gy whilst respecting the published OARs dose constraints.These were compared with plans generated using the 3 CT plans for each patientto deliver a prescription of 7Gy to point A. The plans were compared in termsof the d90 to the HRCTV, v100 receiving 7 Gy/ fraction, and the 2cc doses tobladder, rectum, sigmoid, small bowel and GI total. We also compared the d90per cm 3 of HRCTV as a surrogate of treatment delivery efficiency. Thepaired t-test (T) and pearson correlation coefficient (r) were used with2-tailed significance testing level of 0.05. Results: A total of 90 individualised plans were compared with 90 plans using point A prescription. The median HRCTV volume was 30.7cm 3 (20.1 -72.4cm 3 ), the total combined doses to point A for eachtechnique were comparable with a median dose of 75Gy for individualised planning and 73.6Gy for plans prescribed to point A. Descriptive data comparingthe 2 plans is in table 1:
There was a statistically significant difference in the d90 doses achieved by individualised planning compared to prescribing to point A,also only 4 (13%) cases using IGBTfailed to achieve a dose of >80Gy compared to 19 cases (63%). Although the median doses to the OARs were higher for individualised plans, this is contrasted by the number of cases who would have received clinically significant doses above the accepted dose constraints when prescribing to point A, where 2 cases would have received doses of 88.4 Gy and 90.9 Gy to the small bowel for a non-individualised plan.
When looking at the impact of the HRCTV volume on the dose delivered to the tumour there was a negative correlation for both techniques. There was a stronger association for point A prescribing(r=-0.87; p<0.0001) compared to individualised planning (r=-0.52;p<0.003). Conforming the dose to the tumour volume and shape appears to mitigate for the negative effect of large HRCTV volumes. Conclusions: Individualised treatment planning for each brachytherapyfraction using CT scans allows an increase in the number of patients achievinga d90 of >80Gy whilst staying within the OARs dose constraints. Prescribingto point A without conforming the dose withimage guidance can result in a number of patients receiving clinicallysignificant overdoses to the OARs with most likely serious long term toxicity.
EP-1601
Impact of dose constraints on local control and G4 toxicity in image-guided adaptive brachytherapy for cervix cancer K. Majercakova 1 , R. Pötter 1 , S. Banerjee 1 , C. Kirisits 1 , A. Sturdza 1 , P. Georg 2 , D. Berger 1 , N. Nesvacil 1 , M. Schmid 1 1 Medical University of Vienna, Radiation Oncology, Vienna, Austria 2 MedAustron, Radiation Oncology, Wiener Neustadt, Austria Purpose/Objective: To assess the impact of dose constraints on the clinical outcome in radio(chemo)therapy and MRI based image-guided adaptive brachytherapy (IGABT) for cervical cancer. Materials and Methods: Our study population consists of 225 consecutive cervical cancer patients (FIGO stages IB -IVA) treated between 1998 -2008 by external beam radiotherapy (EBRT) +/-chemotherapy and IGABT. For this retrospective study patients were stratified into two treatment groups: Group 1 (optimal treatment): all dose constraints fulfilled. Group 2 (suboptimal treatment): one or more dose constraints not fulfilled. The following dose constraints (EBRT + brachytherapy dose) were applied: CTV HR D90 ≥85 Gy, D 2cc rectum < 70 Gy, D 2cc bladder <90 Gy. All doses were calculated by summation of the dose of all EBRT and brachytherapy fractions using the EQD2 model (α/β=10 Gy for target volume and α/β =3 Gy for OARs). Differences in event free interval [local tumor control and grade 4 toxicity (surgery necessary) according to LENT-SOMA score] were compared between the two treatment groups. Results: Optimal treatment received 77 (34%) and suboptimal 148 (66%) of the patients. The mean follow-up in group 1 and group 2 was 54 and 49 months, respectively. FIGO stage in group 1 versus group 2 was: stage I 14 (18%) vs. 11 (7%), p= 0.015, stage II 49 (64%) vs. 88 (60%), p= 0.545, stage III 14 (18%) vs. 39 (26%), p= 0.172 and stage IV 0 (0%) vs. 10 (7%), p=0.020. There was a significant difference in the volume of HRCTV between the two groups (Group 1 vs. group 2: 34.2 cm³ vs. 47.8 cm³, p=0.001).
Five-year local recurrence free interval was 92.8% in group 1 and 80.8% in group 2 (p=0.028). Grade 4 rectal toxicity was observed in 2 cases in group 1 and 1 case in group 2. Grade 4 bladder toxicity was observed in 0 cases in group 1 and 2 cases in group 2. Five-year event free interval (local recurrence or G4 toxicity) in group 1 and 2 was 90 % and 79% respectively (p=0.056).
